Gamida Cell (GMDAQ) 25 Feb 202019 Q4 Earnings call transcript

Ladies and gentlemen, thank you for standing by. And welcome to the Gamida Cell Financial Results Conference Call for the Full Year 2019. My name is Sylvia, and I will your operator for today’s call. At this time all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. advised request. call be at being Please Cell’s Gamida Instructions] that is today’s recorded [Operator

would to Investor I Jaren Communications. Now, like go Madden, conference, for Please Vice Miss today’s President of ahead. Relations Corporate introduce and your host

a our Welcome financial for and on we Julian during morning, XXXX. available at an on Earlier everyone. provide results review and is issued Officer, today’s Gamida which and company, the Chief Officer. call call Shai is this Thank across me Tom you, Cell With morning morning Ronit Officer, press our Commercial our to Officer Adams, website our Sylvia on Chief Medical update good progress and release www.gamida-cell.com. Executive Financial Lankry, which Klima, summarizing Simantov, will this financial Chief Chief we results

Following our the remarks up open we Q&A. call for will

make operational we plans, potential statements During our candidates, including may strategies, runway. and development cash our and of objectives, clinical this forward the therapeutic projected operating plans future product expectations expenses looking call, and our about

actual to future new of them time in of future, otherwise. Form filings These with today from from risk project section a our the due to that result time. our in in and may factors, or what of makes as considerations factors represent materially results important may today information, number update the not including SEC as and of forward-looking you we views that the Our only Gamida statements other XXF differ described we we caution events, whether the a

to over Julian. the I'd Now turn like to call

cell this for Cell, are taking blood hematologic Thank and patients everyone rare through of committed the to you morning. Jaren, join for to next-generation cures development us we the thanks with diseases serious therapies. cancers, finding time Gamida At and to

lifesaving transplant. option product of advanced bone is could patients marrow a omidubicel and treatment in for most offer development phase candidate, in X a need Our

NK Gamida year or the we XXXX and potential both natural team. I developing executional investigational, highlight today, in have solid also And our GDA-XXX cell We hematologic advancing for therapy malignancies Cell. expanded our progress killer building made important our programs are tumors. an substantial will and with was

December, Turning study X we malignancies. patients Phase patient cell. in our In risk enrolment with omidubicel first completed in hematologic at high

are quarter we this As a and in X year, are data from report months Phase BLA line approval of to nearly position XXXX, our in expect data with for we two FDA to study quarter guidance second into in would XXXX. fourth submit the top us narrowing for the us XXXX. enable and the Positive the of launch to omidubicel potential

significant U.S. to the cell breakthrough Europe, the represent product field would the next from a and our orphan EU We broadly which omidubicel filing, marrow a bring patients Omidubicel common the is FDA. receive to the us work transplants. therapy ability and to first MAA for The advancement to to for file or drug technical omidubicel streamline use in a will in designation marketing regulatory the application authorization stem document enables has transplant of bone in required year. designation

at commercial advancing also will both We we have potential supply. bring that on-going help out the build is ensure omidubicel key and are activities Lonza approval. manufacturing FDA patients to Work to at following to and sufficient to own reliable required infrastructure facility our

designed hospital omidubicel assistance services and seamlessly to are programs patients. to to paced also develop We comprehensive working bring

Turning to GDA-XXX.

reported represents at creating meeting, and which platform were fourth on half will for understanding annual study NAM the with Haematology for GDA-XXX a the in enhance of multiple functionality at further hypoxic limitation GDA-XXX the preclinical sponsored and very meeting or with meeting the We in that Phase the data These provide donor number of multi-center, omidubicel. study Phase of observed data using responses key multi-does cells. the December, and investigational heavily investigator and technology a advance term and at omidubicel first The lymphoma continue presented we the clinical on American this therapy lymphoma medical update us proprietary preserve marrow new action to in Phase with preserving in the our bone cellular and mimics X/X myeloma. suggests reinforce complete ASH, drug ability application been that this will our the to next submit the a our underlying because Last non-Hodgkin of environment NAM initiate the rationale favorable therapeutic study transplantation the non-Hodgkins The of of data X mechanism designed function year. Based patients of long enable TCT clinical or lymphoma, to approaches. to cells. patients the of to Last our scientific functionality patients in to previously we NAM data be in This a the with pleased Both cryopreserved week, on from using FDA outcomes an are an reported we activities engraftment Society non-Hodgkin's and X/X is quarter pre-treated important required niche focused genetic formulation. year. multiple IND observed stem provide patient has our in prior platform. year engraftment data

We to to GDA-XXX. studies similar action during study initiating process, mechanism we of and of characterize expansion omidubicel NAM the for the are with mechanism are events continuing the biochemical action

past key as depth year, made functions. to as with the we appointments new establish to add expertise several several team key well appointments Over the and management

I'll joined joined and Ronit Chief Officer further Quality Chief Karyopharm now provide for already Klima turn month, and Chief at as submission. to appointed our multiple us BLA global Officer and Officer. previously making us Last instrumental She GDA-XXX. we has Regulatory and Lodie been Chief the rare in diseases. worked Ronit? a Uppal, Jas and Commercial experience a call on our as Tracey regulatory in oncology developing and on Scientific executing to over impact Officer. Medical omidubicel Her update Biogen Plan Tom XXXX, and Ipsen, During strategy positive products is Simantov,

And Thank morning everyone. you, good Julian.

is study most Our of X clinical milestone this year omidubicel. from reporting data our important Phase

and As of compared this designed study Cell Gamida evaluate the X truly company patient is move investigators from reminder, appreciate the allogeneic efficacy helping to novel umbilical field and the a first transplant a conduct trial and omidubicel community. and accomplishment are randomized participation graft, XXX of who blood completion bone cord We the for the was global a marrow patients the transplant standard approximately patients. us a enrolment study safety to to transplant marrow the for the marrow from Phase in bone and bone for in significant the forward. for is support to

mentioned, top line we to a Julian quarter expect data press this via year. the As release report in of second

to will focused would the is the endpoint seven primary effect. a days, difference meaningful engraftment to time neutrophil out be arms. read the two be The a study clinically which of comparing treatment on first The in well powered detect

all transplant. omidubicel currently in improve no half to that any we sponsored also that Phase Additional Currently, graft. cohort endpoints Anemia, can data threatening three which results underwent a will of patients study study, medical rare and an have life this stem a into a Positive potentially donor belief are showed available is needs omidubicel disorder. we’ll second X/X neutrophil enrolled We're the evaluate provide bone who for evaluating reporting the Therefore potentially transplant marrow which a cell patient our treatment patients the the patients reinforce to we in after omidubicel meeting omidubicel consisting curative in completed a as a at haploidentical engraftment outcomes being a with designed first from study the graft. study successfully Aplastic second Last investigator year. of plus option standalone patients cohort, who of and anticipate treated read study severe year, blood the out the analysis.

We greatly K-cells The based data cells, activated our a have program, tumor We're been a key NK continuing second of NK cell the this cell Cellular numbers to cells killer cells to properties. also limitation by for a ADCC. is enhanced to past, The by the utility which functional the highly culture. to NK has an In anti the in report recognize second sufficient of destruction, tumor of natural cells. antibody generate and expect trigger killing cells market therapy. advance year. Natural Antibody-Dependent antibodies to additional that potent GDA-XXX, Cytotoxicity from activity of or therapy tumor ability Killer and binding therapeutic the half study of

at additional recommended to reported from Phase at enrolled, assess combination conducted are We've doses antibody at already Society At technology most ASH limitation. non-Hodgkin's focus all of to with who those I designed the achieved the with complete we activity by non-Hodgkin's this There Among which We my encouraged GDA-XXX. dose. overcome ASH, XX our potentially recently disease. patients after Phase with by Haematology patients, lympho most trials complete there nine with X of monoclonal American and a additional from encouraging lymphoma, myeloma. included of as The patients among re-treated are in pre-treated who safety will in responses was with X observed This University be treated Veronica or advanced also are using a to lymphoma of We were and to subsequently partial nine Minnesota. in multiple evaluated, Phase Bachanova study continue determine the doses meeting, patients The X reported study on patients which safety and dose oral patient data presentation dose, observed. date the clinical were the patient and an to particularly patients see heavily the very on-going objectives, data achieved with NAM infusion depletion. Dr. we with of to three without increasing of five our responses GDA-XXX being a single of X this response. was population was XX patients. a activity with patients in an response with patients Since lymphoma, is comments

suggests patients. were months because that out patients nine becoming of six of a had therapy Richter it with in post So tumor all, is interesting, elicit a continued transformation a adapted scientifically GDA-XXX before of shrink response. approximately there one and and immune response. history responses these over This and interest, complete XX clinically to Of very CLL that complete

dose activities on toxicities this the required to We also no activities neuro tumor think to which first Shai fourth toxicity in formulation. GDA-XXX. highly the IND no is the X/X compelling a scale to observed. strategic continue were profile and the no strikingly experience, operational an study. syndrome, call of up in Phase GvHD, We're our focused with lysis in-human GMP will of initiation In our our we the key pleased There been of for be financial in we are that, with safety includes multidose I preserved data on Simultaneously, to to With summary, enable no limiting review year. over study results. lymphoma quarter, enable multicentered, submission working patients and turn has cryo next

good and financial full Ronit will you, review XXXX our This Thank results. morning, morning year everyone. I

of to equivalent compared million As as for and cash, December XX, $XX.X December available cash total sale XXXX we of XX, $XX.X had million XXXX. securities of

for the services organization activities to As can expenses. organization. to million of the proceeds well advancements organization, the XXXX. to clinical as same million and the July development commercial offering and $X.X Net due to accounting million. cash million in year by GDA-XXX was compared $X.X mainly gross as the $XX.X for year in $X expenses non-cash relating due were as the of These establishing increase programs for net by million was million to was XX of The XXXX. the the commercial year income XXXX, liability omidubicel with a the related from net in for the royalty-bearing The with implementation loss expenses as other and expenses offset increase as of from headcount; finance as expense to non-cash and million The well expenses million a establishing commercial to we General re-valuation of being due administrative of P&L. publicly a increase were due $XX.X in professional million related a non-cash services expenses, a $X.X the associated IFRS the XXXX. million and Israeli million of compared for Research the in total reminder, related million. Net and offset we expenses increase additional in last $XX.X other were XXXX. our expenses, to was standards. established $XX.X item $XX.X was line year, completed The the expenses expenses total resulting $X.X in $X.X Innovation in professional compared to to primarily Authority [Indiscernible] were million well mainly mainly $XX.X was $XX.X for to decrease period following loss and new hiring and million to $XX and $XX.X increase commercial finance year, traded compared warrants, income the grant million rent company

of $XX financial expect to report the line from trigger expect activities board into for the of Phase are omidubicel additional expenses half top readiness. the potential second million of of million. range quarter. Positive data the We months we studies the year, which to year, first for from to clinical providing the additional today, guidance omidubicel X six commercial including data operating the and to in $XX activities to support would study in second the Therefore

addition, In on that into that we'll support current both our year. the commercial may of cash anticipate Julian. that current on-going operational the that, I total This clinical our including guidance activities funding our exclude operating programs to that our this fourth back and may With plans, rate the we continue to over our turn quarter will will is business cash [ph] received based be assumption position run and/or additional any undertaken. or be advance call readiness activities development

quarter, year. year year. report anemia data file second aplastic for six, of a for from omidubicel anticipated meeting top year. by I from which report BLA milestones omidubicel X the GDA-XXX And half milestones, first in has XXXX IND medical I the Two, transformational four, conclude, half X/X data value hope a fourth the activities omidubicel present as line we will for second One, patients the of of Shai. reviewing be the required And at Shai. in quarter. are data in the on present on fourth for additional deliver data the will Phase severe follows. quarter. will Thanks, the positive the in Phase half GDA-XXX with the assuming XXXX, for the thanks to focused our very potential shareholders. which in second drive submit the to the our conclude Three, we the company. omidubicel additional Five, study are data the in finally,

delivering a strong on therapies the forward in team our progress. to of have committed we next generation patients, cell to We place look and updates to providing

Now we will call questions. Operator? open the for

first your Butler of comes Instructions].And [Operator from Securities. the line JMP Jason from question

Hi. Thanks for on taking progress. the questions and the congrats

couple any earlier in to you a want release will we will other other components endpoint? any primary are safety there be then just end it line of follow example then endpoints that the readout. section I we secondary primary to on data and just get BLA, And X Phase commercial line on have up the the mentioned gating What should point. the on top omidubicel that be the readiness. the release of? will kind clarify; top or aware Just CMC -- a I perspective, BLA for the beyond clinical And the from submission item focus

Okay.

me direct part your Let Ronit first about to the the endpoints. talk to question of

Sure. Thanks the question. for

what's and endpoint neutrophil so on get rapidly endpoint. in, top to the and the objective a primary which an from engraftment, that data read is analysis study And is the could results report line important. built we we quickly time real the So data, out that reading

take won't data of we longer will have numbers, as endpoints the mature at we'll which and to of rest as And announcement sort but other other well full top of endpoints read line any the contain demographics data will the time out. presented those and and steady that it. So that basic that have some set the

section And is the clinical finalize the section, the that the ready fourth the is Jason preapproval inspection ongoing to three to important non-clinical BLA, the submit sections expectation contemporaneously is be happen that to One and study that the there which ongoing, complete. regards we BLA the BLA, to to we note clinical finally with to CMC will and virtually BLA. in will filing section maybe course BLA. of And need report is The quarter. are the with is important of its

the to So will and inspect for BLA need the manufacturing the site, accepted. be FDA the site to

Great. the continue anticipation to transplant can launch? thanks awareness helpful, omidubicel today you're throughout centers is in on of and Very talk the doing the And XXXX and just Julian. believe key side, work then to about and where with in the U.S. you build commercial in a awareness company, you

I'll Yes. to answer question. ask that Tom

morning, discussed centers omidubicel the opportunity Klima. The in Yes, this Tom XX United about the transplant is for before, patients relatively we've good Jason. to think -- hi States. I concentrated but

to remind XX% were and in portion We you the those in of existing already relationships trials, concentrated just centers. So a awareness. clinical have about so is of opportunity we the in good XX transplant

working as also to and our tune campaigns XXXX disease of our unmet well addition foundational projections. our continue need some in and completing state so on finding the market fine research throughout are as We understanding that educational to we internal awareness expanding

taking for the question. Great. Thanks

Your RBC Capital line Renza next comes Gregory question of the Markets. from from

and my on thanks progress team, questions. the and for congrats Julian Hey taking

pleasure. Our

just I how just time the omidubicel perhaps top back Thank the you. on to clinical additional just line and from context meaning on we should I a that just days at with of benefit could in expectations benchmarks want out? heard engraftment if and you your mention that to provide keep of correctly, point read and that can you're perhaps specific the to in Thank neutrophil looking how if readout, I that and run and you. color turn marketplace the Julian, end detecting be and the perhaps of seven translation mind, any think difference that a or that that

Ronit.

ahead Yes, do. do and ahead go that. I'll go I'll and thanks.

represents the takes So very the harsh that patients infection has they fighting the time and get back patient after life other is their cells grow by to day conditioning it neutrophils infections obliterated serious they've complications. into circulation to the threatening neutrophil that or very to And be cure again chemotherapy engraftment or for very get that day the neutrophils, lymphoma. every low leukemia can or been a

they that healthier that or is day And immune grown so hospital. a can have they another not have neutropenic and where they're their back, leave every system have cells day where potentially the

medications less time improving an as improve infection, the for But days, or by with and graft. clinical in for the that's weeks times unrelated impression have vocal a has saving time XX for them So XX sometimes has hospital neutropenia donors neutropenia hospital, transplant blood marrow cord much transplant. after in even that something numbers will opportunity this that's save We've weeks has that, in days in at that patient upon infection, sooner And this for seen Most the fighting or XX save time, expensive for and of complications XX years And time -- neutropenia. of of days to that three transplant taking patients are place of our couple meeting children. significance a the the who complications transplant patients such longer them bone other within complications classically therapies of save very And to in with the less any cord with is points real community more. patients to is takes associated engraftment source less had been improvements as them would patients. and sibling engraftment of days such been with neutrophil all. like supported days the the neutrophil be historically

proposition and a feel terms we difference so, what think for patients sort in of looking clinically impact in make meaningful week difference. difference, and well and the to value XXX of are of the we're clinically of about that meaningful a very with of powered the In the the we're a clinically difference for, way patients or detect We do system. would of the

has So why of But, that implications. less patients every real, something to I That's incredibly potential day I seven difference. useful. meaningful mentioned that's important would be and the single day really neutropenia think is

Great. Thank more helpful. just you. one That's me. from very And

about and learned and the out your some do comment that's you all a from Just the with the omidubicel utility that's practice to Phase approval I'm during you a learned, commercial curious, underway how as with now. X very at you've that's pending, product the you read respect has data any met timelines, but what been pace. reception short experiences of progressed, have satisfactory what much. Thank certainly commercial profile and just the the so enrollment patient such obviously time you've of for potential been

the that beginning of and Ronit, ask maybe I’d also you can to you answer then start comment. Tom,

Absolutely.

So given -- fantastic trial over centers, their of personal transplant some with conducting globally sites, opportunity intense at engage on on XX basis. a us the staff really very clinical all to has and a investigators and

working with really been these teaching the then them, over inside two. we've through things with of year and with them, past them So or going centers, them, engaging all

really been practices, learn So Tom. omidubicel. opportunity the about to to that's as them a learn about Gamida the taught lot, to centers, and have as us learn and it's Cell a And well about about great

the both in in if community there's existing sorry, of just States. shortcomings. researches we're doing response done. also some it we've current product as for profile we've omidubicel the to Greg, that United transplant the shared of of the to whatever reason, pleasantly never sorry – the you both unmet who of the And add Oh received. And United well you has surprised States the I'm past Ronit, that, pleasantly terms and patients but been to were and to in remember centers significant done some transplant being the been be the make modalities target transplants amount a need continued outside transplant thought in in today, market in I the very

us in product about profile would telling target some telling telling more that they're it. they'll transplant to modalities. it And place that not patients of get excited to they're us physicians, They're use a us show it. we will use the they're of other only that that they when So they

addition we've for strategic “Be that body side, add on that, is The I'd which relationship patients formed helps In like advocacy matched transplant. the governing get with to a Match” patient the

we And working them closely we the cord to so very patients. are cells ability with which coordinate the expand from blood stem for umbilical to source

at So will we more ongoing, from the patient the have advocates both the enhanced every creating be other an level, are primary work we and when physicians, this awareness. And all endpoint. obviously, poignant,

Great. the for Thank you taking very much question.

comes of line question Luchini Capital. next Matthew Your BMO the from from

Hi, good questions continued from on A Thanks and the progress. morning guys. couple me. the for congrats taking

broader target thinking know guess population. core I for some awareness about and target think run heard around the study has in by potential color as we've guess, there's the first, been actual a but the we centers. So I population But transplant also we about population, the population the

And how label, just I we what be that omidubicel -- to that this from come could how expectation thinking secondly you that that that out So the such on population? wondering reimbursed bigger might be I'm could and probably about be reimbursement, a is similar think will then should the CAR-T. address of

multi-dose, where we've on Thank little color study multi-center was then here? ability more on product? being things I curious preservation lastly, just stand thinking we to and how you. in about XXX, get should just bit prior to So cropreserve dynamics about And enabling about the the of past was in terms a a hoping reimbursement key step talked to be

real Okay, of we're world modalities Ronit, other as data study comment can transplant? on well you the looking doing at

absolutely. Yes,

with transplant the is concurrent the we to study. Blood a for the population. And in around of of we're population Transplant transplant the place where and kind world study we that's address in real Center Marrow terms of Phase our population collecting message in one our doing us and can collaboration on will help transplant So modalities CIBMTR can that today, where our X of results so omidubicel broader International broader ways through data Research, -- concurrent data other the other fits patients that the transplant build that context in so the

earlier, donors around was and presented this XX XX between days. it's average XX at recent also days days on Haploidentical to commented whether blood unrelated or this, cord modalities And all blood other that XX itself meeting and by TCT is Ronit connect, matched donors days, cord engraphed on the

believe graft. terms a Again, that are be awaiting transplant may we omidubicel demonstrate that. the best-in-class So in of we to data

And then, some, to add that your believe CAR-T just and it There out reimbursement. through this similarities Tom, similar be and reimbursed answer will likely mechanism. reimbursed carve to to how omidubicel to think is question we I a are around that will be

only our CAR-T that but patient XX% pair we product about difference for So mechanism. also and payers study, just then will Based demographic XX% payers commercial believe would our the the is not that likely about pay carve through pay for other. omidubicel speak the a out center transplant, between all The main omidubicel. to in mix know on would I and be with roughly,

takes and a that you larger population, that believe CAR-T of Medicare of One is had Medicaid it have commercial reimbursed [Indiscernible] little the entire the process longer the and reimbursed be as that the know processes do. mechanism. But a will and it'll some we're than be the faced challenges much confident they bit that

manufacturing. GDA-XXX We on it. comment me let did lastly, And

into to do and GMP how announced We format, this need still but get IND. and that and have an XX% a preserve saw About qualification recovery. we've engineering very to cryo with we runs cells filing runs, successfully and good both recovery, optimize the learned to prior

cryo an the that to much will filing take be able be a of remainder year this to us So that's to an of multidose approach. product going the multicentre, preserved IND to enable have off shelf

to top quickly Thanks. X in no safety going we the well only thanks. When format. as data information be question. Great, released be getting efficacy just And the is or clarification standpoint? line are press primary yes, to Phase it Are going

Ronit, going announce? to we’re reiterate you can what

of sort be safety information. statement no There overall about on point. be there'll based at no the detailed may Sure, information safety broad a detailed look, but that safety

had I to get we safety bi and you would we just audience board signals had the external monitoring no and remind have and on and safety that have are they date. And every a annual study month, data meet they that data the concerning throughout basis,

Okay. the questions. all Thank taking you for

comes line Your Company. the Chad from Messer next & of Needham from question

we of and follow what start but data. that morning Obviously, written in terms upcoming in treatment? are the for which is share And my they going patients can possible thanks the more amount to Good terms additional we if it's with wondering the that protocol additional going taking more questions. would we of you be should we're treated? a XXX re get, Maybe see can way NHL Great. to with in up data expect patients is potentially of important just

would you to like as well. handle Ronit, that

that. to happy Yes, take Thanks, Chad.

So, and patients additional the re be been up the protocol next data yes under in for the is, certain additional update. to treatment additional -- allow there follow has there And conditions. will is amended

have data will well. as And more on patients, be been treated re so who there

right. Very All exciting.

at specific on manufacturing. of And then what terms you'd know, maybe commercial of couple to several of preparedness. Looking made like goals the comments the do I forward on a already, for the time but at to you that have have that. throughput omidubicel you've in launch sort

of got You've the for Be-The but got know the of cord view patients? match you've of the availability? I getting with most your your and partnership in-house state of availability blood on a that Match what's Lonza

in I an is have supply more million year, that and the on-going babies this critical born cord in year supply than you every education So the launch there enough process, our are will about be United will success. States. remind to blood since four we

cord And quantify better are to here, not will I doing we years three of uptake still supply to between thousands the projections research but So market launch be have think to blood limiting. transplants the multiple in five. these out

scaling were we So up accordingly.

Great. Thank All right. you.

the next Your from Mark Instructions] Oppenheimer. of question from [Operator line comes Breidenbach

questions. taking And the Hey, thanks good morning. for

of terms haploid haploid fairly trial especially versus arm, So of over randomized and survival. at weekend favor to the results seem a overall saw TCT, cord study double a blood the we transplant, that in transplant certainly large from

if the simply approved? for enough any wondering, transplanting versus us approval I'm you and give reduce I'm omidubicel advantage a wondering goal you’ve of when why is overview plans to just think potential can also So post omidubicel haploid any have of to omidubicel to you is once do randomized raised with trial the -- you if survival an

further So let to analyzing our to reduced you study. me just having this impossible in was begin. those presentation? it referring have any seen these -- CTN-XXXX to study The used so cooperative a intensity think trial current it's group I do patients the trial, conditioning, comments the Ronit, compare patients you which

for may for intensity I not but are think conditioning that's older this It the was population, frail conditioning key appropriate in most appropriate Reduced Yes, not transplant. healthy a getting robust be is adults adults who included of the point. considered group study. or any longer for the that

we're type So doing. for unit these to patient. double bit these single -- for that very is hard We're reason of than transplant, also without double omidubicel core transplant a cord different the a transplant rather a interpret using of it than the results included

yes, giving results and related And of in in of who think in omidubicel did terms that our related were sort benchmarks show the of who will think about I to interesting controls achievement our of historical mortality So core. X that issues study think, instructive some terms got standard Phase us I treatment results got patients mortality, are. what decrease I the what's compared

well. have results if and their that field. certainly to X, the the rest forward So we impact the the on as seeing an results looking we're Phase X clinical And in of see then into context And the patients. with we that will results Phase anticipate putting them recapitulate observe that that we'll important

versus a Okay, maybe need of so randomized half not run a trial to you’re seeing them.

So let is a perfectly on that. first me comment of -- approach. There all transplant Haploidentical legitimate I think are

If you haploid a donor. have

haploid. will treatment worse where a world doing should are XX% suboptimal have to probably that about We outcomes. teach real the and They population a get studies, of least patients of with randomized I fits age that think data getting However at portion transplants lot the omidubicel XX additional in not over about they And donors. of paradigm. are the us regards haploid think the

we plan post a we do trial do approval a to currently, have not with So haplo. randomized

Okay. Got it.

lymphoma that Bachanova will transplant then to patients to it upcoming on safely response? in NHL more open seeing patients be receive tDLBCL or and company you'll subtypes we to in post your going NHL? we're a go who And you'll a on on allowing follicular I'm one focusing sponsored to GDA-XXX of flavors the Can other curious Just enrolling be be respond same if study quick were Dr. trial. that or assume be

lymphoma types are population. of the cell. patients and are tDLBCL and There with mediastinal of the rare MALT XX% follicular Mantle either lymphoma, or of Well largest

the future yet, will study the we will decisions as make designed time. at haven't year progresses, and a KOLs meeting We we and will -- with those be

All for taking right. your questions. Thank you

And this further questions. time, will call Julian. back turn the show I at I now to no

everyone us call. So on joining for thank today's you

ahead, excited really on and forward updates to year. our opportunities that the the are We progress sharing lie about Operator? throughout look

today's concludes call. that gentlemen, and Ladies

may You now disconnect.